Abstract:To study the survival ability of cerebellar cells and genetically modified cells transplanted in the brains of mice and monkeys and whether the transplanted neurons correct and improve the cerebral function disorders.Suspension of cerebellar tissue from 13-day-old C57BL/6 mouse embryos was transplanted into the cerebellum of 3-month-old BALB/c mice with Purkinji cell degeneration. Since one week after the transplantation, six mice were killed every week till the 8(th) week to examine the cerebellar tissue by immunohistochemistry. Genetically modified neuroblastoma cells with tyrosine hydroxylase (TH) gene and substantia nigra cells of naturally aborted 12-week-old human embryo were implanted into the caudatum nucleus of two monkeys with Parkinson's disease caused by injection of 1-methy-4 pheny-1, 2, 3, 6-tetrahydropyridine. After the operation, the monkeys' symptoms were observed. Six months later, the monkeys were killed. The transplanted areas were examined histologically and immunohistochemically. On the basis of the animal experiment, cerebellar tissue suspension of 9 to 12- week-old human embryos was transplanted into the cerebellum of 6 patients with severe cerebral atrophy, and suspension of substantia nigra cells and adrenal medullary cells from naturally aborted human embryos was transplanted into the caudatum nucleus of 5 patients with late Parkinson's disease. Then the patients were followed up to observe the symptoms.Surviving transplanted embryonic cerebellar cells could be seen in the cerebelli of recipient mice. Differentiation, maturation, and migration into the granular layer of Purkinje cells could be seen. Axons and dendrites grew from the newly generated Purkinje cells. Many mature nerve cells were monoclone antibody staining positive. The myodynamia of monkeys increased and tremor was alleviated, and torsion spasm was remarkably remitted 5 and 7 days after the transplantation respectively. Genetically modified cells with tyrosine hydroxylase gene could be seen and were pale brown with immunohistochemical staining in the cerebral microcapsule of monkeys. Five of the 6 patients with severe cerebellar atrophy and 5 patients with late Parkinson's disease showed improvement of symptoms beginning from 2 weeks after transplantation. The average score of Webster's scale in the patients with Parkinson's disease decreased from 21 to 11. Th3 condition of two patients with cerebellar atrophy and 2 patients with Parkinson's disease continued to improve or remained stable after two years' follow-up. The condition of other patients had worsened.The immature embryonic nerve cells and transgenic TH-cells survive in the brain of recipients and have the potential to regenerate neurons and improve the function of central nervous system.

Nerve-cell grafting in Parkinson's disease.

Neural grafting for Parkinson's disease: challenges and prospects

Transplantation in Parkinson’s Disease

History of cellular grafting for central nervous system repair-A clinical perspective

Neural Transplantation and Trophic Factors in Parkinson's Disease: Special Reference to Chromaffin Cell Grafting, NGF Support from Pretransected Peripheral Nerve, and Encapsulated Dopamine-Secreting Cell Grafting

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells

Therapeutic application of stem cell technology toward the treatment of Parkinson's disease.

Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease

Neural-tube-derived Neuroepithelial Stem Cells: a New Transplant Resource for Parkinson's Disease

Human Umbilical Vein-Derived Dopaminergic-Like Cell Transplantation with Nerve Growth Factor Ameliorates Motor Dysfunction in a Rat Model of Parkinson’s Disease

Cell therapy for Parkinson’s disease with induced pluripotent stem cells

Neuronal Replacement in Stem Cell Therapy for Stroke: Filling the Gap

Human stem cell transplantation for Parkinson’s disease: A systematic review of survival and maturation of progenitors derived from human embryonic or induced stem cells in Parkinsonian models

Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery

Dopamine Cell Therapy: From Cell Replacement to Circuitry Repair

Fetal Intra-Nigral Ventral Mesencephalon and Kidney Tissue Bridge Transplantation Restores the Nigrostriatal Dopamine Pathway in Hemi-Parkinsonian Rats

Long-term Restoration of Nigrostriatal System Function by Implanting GDNF Genetically Modified Fibroblasts in a Rat Model of Parkinson’s Disease

Intracerebral Transplantation of Differentiated Human Embryonic Stem Cells to Hemiparkinsonian Monkeys.

Cell Therapy in Parkinson's Disease: Host Brain Repair Machinery Gets a Boost From Stem Cell Grafts

The stem cells as a potential treatment for neurodegeneration

Intracerebral transplantation of nerve cells and genetically modified cells for disorders of central nervous system, a basic and clinical study]